drugset / Trial / NCT01634360

Long-Term Safety, Tolerability and Efficacy in Perampanel Treated Parkinson's Disease Patients With Motor Fluctuations

NCT01634360

Phase 2 Terminated 185 enrolled Eisai Inc.
NaSingle-groupOpen-labelTreatment

Summary

A 48-month open label multi-centered extension study to evaluate the long-term safety, tolerability and efficacy of E2007 in patients with Parkinson's Disease with "wearing off" motor fluctuations and "on" period Dyskinesias.

Timeline

Start
2004-11
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Perampanel Small molecule 1 mg
Subject Perampanel Small molecule 2 mg
Subject Perampanel Small molecule 3 mg
Subject Perampanel Small molecule 4 mg

Indications